Quick Answer
AMGEN INC reported Cash and Equivalents of $9.13 billion for fiscal year 2025.
AMGEN INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $9.13B | -23.8% |
| 2024 | $11.97B | +9.4% |
| 2023 | $10.94B | +43.5% |
| 2022 | $7.63B | -4.5% |
| 2021 | $7.99B | +27.5% |
| 2020 | $6.27B | +3.8% |
| 2019 | $6.04B | -13.1% |
| 2018 | $6.95B | +82.8% |
| 2017 | $3.80B | +17.2% |
| 2016 | $3.24B | -21.8% |
| 2015 | $4.14B | +11.1% |
| 2014 | $3.73B | -1.9% |
| 2013 | $3.81B | +16.8% |
| 2012 | $3.26B | -53.1% |
| 2011 | $6.95B | +111.3% |
| 2010 | $3.29B | +14.0% |
| 2009 | $2.88B | +62.6% |
| 2008 | $1.77B | -12.4% |
| 2007 | $2.02B | +57.8% |
| 2006 | $1.28B | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.45B | +4.8% | +17.7% |
| June 30, 2025 | $8.03B | -13.7% | -8.9% |
| March 31, 2025 | $8.81B | -9.3% | -26.4% |
| December 31, 2024 | $11.97B | +9.4% | +32.9% |
| September 30, 2024 | $9.01B | -74.1% | -3.1% |
| June 30, 2024 | $9.30B | -72.8% | -4.2% |
| March 31, 2024 | $9.71B | -69.2% | -11.3% |
| December 31, 2023 | $10.94B | +43.5% | -68.5% |
- AMGEN INC showed a decrease of -23.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2006–2025 period, AMGEN INC’s cash and equivalents has grown by 611.5% (from $1.28 billion to $9.13 billion).
- The most recent figure is from AMGEN INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: